Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus MONISTAT DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus MONISTAT DERM.
KERYDIN vs MONISTAT-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Miconazole inhibits fungal lanosterol 14α-demethylase, a cytochrome P450 enzyme, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
Topical: Apply once daily to affected areas for 2-4 weeks. Vaginal: One 200 mg suppository at bedtime for 3 days, or one 100 mg suppository at bedtime for 7 days, or one 1200 mg suppository as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal elimination half-life is approximately 24–30 hours, supporting twice-daily or once-daily dosing for dermatologic infections.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Primarily fecal (biliary) elimination as unchanged drug and metabolites; <1% renal excretion of unchanged drug.
Category C
Category C
Antifungal
Antifungal